Is Pralsetinib included in the medical insurance reimbursement catalog?

Pralsetinib is a targeted drug targeting RET gene fusion-positive tumors. In recent years, it has been approved for marketing in the domestic market and has become an important treatment option for some patients. Although the original drug Platinib has entered the domestic market, it has not yet been included in the national medical insurance reimbursement list, which makes the high price of the drug a major obstacle to patients' medication burden.

Currently, the common packaging specifications of Platinib in the domestic market are 100mg 60 tablets and 100mg 120 tablets, with higher prices. The price of a box is generally more than 20,000 yuan, and in some areas the price is even as high as 60,000 yuan, which is a considerable financial pressure for many patients. In comparison, original drugs in overseas markets are more expensive. The price of a box of 60 pills usually fluctuates between 40,000 and 100,000 yuan, further limiting patient accessibility.

It is worth noting that generic drugs of Platinib have been developed in overseas markets. The ingredients of these generic drugs are basically the same as those of the original drug, but the prices are significantly more affordable. For example, the price of 120 generic drugs produced in Laos is about more than 3,000 yuan, which is far lower than the market price of the original drug. This provides patients with more economically viable options, especially if they are not covered by domestic medical insurance.

Generally speaking, although platinib has been successfully launched in China, it is not covered by medical insurance reimbursement, resulting in high medication costs for patients. With the gradual promotion of generic drugs and the adjustment of relevant policies, the accessibility of platinib is expected to increase in the future. When selecting medications, patients should take into account their own financial situation and treatment needs, reasonably evaluate the pros and cons of original drugs and generic drugs, and actively communicate with doctors to formulate the most appropriate treatment plan.

Reference materials:https://gavreto.com/